266. 家族性地中海熱 Familial mediterranean fever Clinical trials / Disease details
臨床試験数 : 28 / 薬物数 : 22 - (DrugBank : 5) / 標的遺伝子数 : 14 - 標的パスウェイ数 : 59
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05190991 (ClinicalTrials.gov) | October 5, 2021 | 3/11/2021 | Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean Fever | An International Multicenter Open-label Clinical Study of the Safety and Efficacy of RPH-104 for Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of Colchicine | Familial Mediterranean Fever;FMF | Biological: RPH-104 | R-Pharm International, LLC | Atlant Clinical LLC;Center for Pharmaceutical Analytics LLC;Unimed Laboratories CJSC;Data Management 365 | Recruiting | 18 Years | 80 Years | All | 60 | Phase 2 | Armenia;Georgia;Russian Federation |
2 | NCT05092776 (ClinicalTrials.gov) | April 29, 2021 | 9/9/2021 | Efficacy and Safety of RPH-104 for Resolution and Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of Colchicine | International, Multicenter, Double Blind, Placebo-controlled, Randomized Clinical Study of Efficacy and Safety of RPH-104 for Resolution and Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of Colchicine | Familial Mediterranean Fever;FMF | Biological: RPH-104;Drug: Placebo | R-Pharm International, LLC | Data Management 365;Atlant Clinical LLC;R-Pharm;Center of Pharmaceutical Analytics LLC;Unimed Laboratories CJSC | Recruiting | 18 Years | N/A | All | 60 | Phase 2 | Armenia;Georgia;Russian Federation |